Who
Faisal Ghiath Sukhtian
Director
Company insider
Files Form 4 as: Director and 10% owner, Outlook Therapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 6
- Sells
- 0
- Bought
- $389K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 31 Oct 2017
- Last trade
- 29 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 29 Jul 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K95,398 at $1.05 | filing |
| 29 Jul 2026filed 29 Jul 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K95,398 at $1.05 | filing |
| 27 May 2026filed 27 May 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K122,174 at $0.4093 | filing |
| 27 May 2026filed 27 May 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K122,174 at $0.41 | filing |
| 3 Oct 2025filed 3 Oct 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —117,296 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —286,734 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,323 at $0.00 | filing |
| 3 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,771 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,636 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —134,430 at $0.00 | filing |
| 7 Mar 2024filed 8 Mar 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,441 at $0.00 | filing |
| 4 Oct 2023filed 5 Oct 2023 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —372,671 at $0.00 | filing |
| 29 Mar 2023filed 31 Mar 2023 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,065 at $0.00 | filing |
| 7 Oct 2022filed 11 Oct 2022 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $39K30,000 at $1.29 | filing |
| 5 Oct 2022filed 7 Oct 2022 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,878 at $0.00 | filing |
| 23 Mar 2022filed 24 Mar 2022 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,878 at $0.00 | filing |
| 2 Dec 2021filed 2 Dec 2021 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K18,000 at $1.40 | filing |
| 5 Oct 2021filed 7 Oct 2021 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,753 at $0.00 | filing |
| 19 Apr 2021filed 20 Apr 2021 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K10,000 at $1.82 | filing |
| 24 Mar 2021filed 26 Mar 2021 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,873 at $0.00 | filing |
News
Outlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerOTLK · manilatimes.net · 9 Oct 2026Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor DiscussionOTLK · manilatimes.net · 6 Oct 2026
0 headlines in the last 90 days name Faisal Ghiath Sukhtian; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.